The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia.

Détails

ID Serval
serval:BIB_972E40B3B71A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia.
Périodique
Virchows Archiv : An International Journal of Pathology
Auteur(s)
La Rosa S., Franzi F., Marchet S., Finzi G., Clerici M., Vigetti D., Chiaravalli A.M., Sessa F., Capella C.
ISSN
1432-2307 (Electronic)
ISSN-L
0945-6317
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
454
Numéro
2
Pages
133-142
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
Acinar cell carcinoma (ACC) is a rare pancreatic cancer which may be difficult to distinguish from other solid nonadenocarcinoma tumors. The diagnosis depends on the demonstration of acinar differentiation, obtained with antibodies recognizing various pancreatic enzymes that, although specific, show different sensitivity. The C-terminal portion of the BCL10 protein shows homology with carboxyl ester hydrolase (CEH), an enzyme produced by pancreatic acinar cells. We investigated the usefulness of a C-terminal BCL10 monoclonal antibody in the diagnosis of ACCs. We examined normal pancreases and different pancreatic tumors including ACCs, mixed acinar-endocrine carcinomas, ductal adenocarcinomas, mucinous, serous, solid pseudopapillary, and endocrine neoplasms. In addition, various normal tissues and cases of pancreatic metaplasia of the gastroesophageal mucosa, cases of ectopic pancreas, gastrointestinal endocrine tumors, salivary and breast acinic cell carcinomas, gastric adenocarcinomas with and without acinar differentiation, and hepatocellular carcinomas were studied. BCL10 immunoreactivity paralleled that of CEH and was restricted to acinar cells of normal and ectopic pancreas, of pancreatic metaplasia, and of ACCs. The anti-BCL10 antibody was more sensitive in detecting ACCs and pancreatic metaplasia than antibodies directed against other pancreatic enzymes. We suggest using BCL10 antibody for diagnosing pancreatic tumors and whenever an acinar differentiation is suspected in gastrointestinal neoplastic and metaplastic lesions.
Mots-clé
Adaptor Proteins, Signal Transducing/analysis, Adaptor Proteins, Signal Transducing/immunology, Antibodies, Monoclonal/immunology, Biomarkers, Tumor/analysis, Carboxylesterase/analysis, Carcinoma, Acinar Cell/diagnosis, Humans, Immunohistochemistry, Metaplasia, Pancreas/pathology, Pancreatic Neoplasms/diagnosis, Sensitivity and Specificity
Pubmed
Web of science
Création de la notice
06/09/2016 14:00
Dernière modification de la notice
20/08/2019 14:59
Données d'usage